The European Medicines Agency has approved a new oral formulation of glibenclamide for the treatment of neonatal diabetes mellitus in newborns, infants and children. The new formulation meets the unmet need for patients with neonatal diabetes. About Neonatal Diabetes Neonatal diabetes is an extremely rare form of diabetes that is diagnosed in the first six months of life. It is life-threatening and debilitating because of the symptoms caused by high blood sugar levels.
How Does Glibenclamide Work? In newborn babies with neonatal diabetes, insulin is produced by the insulin-producing cells but it is not able to get released into blood because of dysfunctional KATP channels. Glibenclamide controls the release of insulin from insulin-producing cells in the pancreas by attaching to an ATP-sensitive potassium (KATP) channel. Glibenclamide's effect on the KATP channel restores the cells'…
